311
Views
13
CrossRef citations to date
0
Altmetric
Hematology

Hemoglobin A2 (HbA2) has a measure of unreliability in diagnosing β-thalassemia trait (β-TT)

, , , , , ORCID Icon, , , , ORCID Icon, & ORCID Icon show all
Pages 945-951 | Received 18 Dec 2017, Accepted 29 Jan 2018, Published online: 15 Feb 2018
 

Abstract

Introduction: Detection of β-thalassemia trait or carriers (β-TT) depends significantly on an increase in Hemoglobin A2 (HbA2) levels, which is found at low levels (<3%) in normal healthy individuals and elevated levels (≥3.5%) in β-TT individuals. The study was designed to evaluate the reliability of the diagnostic parameter HbA2 in the differentiation of β-TT and non-β-TT in Saudis.

Methods: The widely used high performance liquid chromatography (Variant II Bio-Rad) was used to measure HbA2 levels in blood. Sanger sequencing was used to screen the variation in globin genes (HBB, HBD, HBA1, and HBA2). All the study subjects were divided into βTT and non-βTT (wild) categories based on the presence or absence of HBB variations and further sub-divided into false positive, true positive, false negative, and true negative, based on HbA2 values.

Results: Out of 288 samples, 96 had HBB gene mutations. Of the 96 β-TT samples, sickle cell trait (SCT) samples (n = 58) were excluded, while the remaining (38 β-TT) were included in the detailed analysis: seven subjects with the HBB mutation had normal HbA2 (<3%), and three were borderline (3.1–3.9%). The remainder (n = 28) had an elevated HbA2 level (>4%). Based on HbA2 analysis alone, both these groups would be incorrectly diagnosed as normal. Similarly, of the 189 non-β-TT samples, 179 had normal HbA2, eight had borderline HbA2, and two had a HbA2 level above 4%. Based on HbA2 analysis alone, borderline and >4% HbA2 individuals, negative for β-TT, can be incorrectly diagnosed as carriers.

Conclusion: Given the percentage of samples falling in the HbA2 “borderline” and “normal” categories, it can be concluded that HbA2 has a measure of unreliability in the diagnosis of β-thalassemia carriers.

Transparency

Declaration of funding

This study was supported by The Deanship of Scientific Research, Imam Abdulrahman Bin Faisal University (Grant No: 2012186; 2014024; 2015292; 2016-077-IRMC), the King Abdulaziz City for Science and Technology (Grant No. LGP-35-204; LGP-32-3 and LGP-36-132), and the National Science Technology and Innovation Plan (Grant No: 12-MED-2798-46).

Declaration of financial/other relationships

The authors have no financial/other relationships to disclose. CMRO peer reviewers on this manuscript also have no relevant financial or other relationships to disclose.

Acknowledgments

We would like to thank Ranilo M. Tumbaga, Horace T. Pacifico, and Jee Entusiasamo Aquino for their assistance and technical expertise.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.